Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Literature
1.
Onoue M, Terada T, Kobayashi M et al (2009) UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol 14:136–142CrossRefPubMed
2.
Hoskins JM, Goldberg RM, Qu P et al (2007) UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 99:1290–1295CrossRefPubMed
3.
Takano M, Kato M, Yoshikawa T et al (2009) Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study. Oncology 76:315–321CrossRefPubMed
4.
Ichikawa W, Araki K, Fujita K et al (2008) Re: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 100:224–225CrossRefPubMed
Metadata
Title
Indispensability of UGT1A1*6 genotyping in Japanese cancer patients treated with irinotecan
Authors
Masashi Takano
Masafumi Kato
Tomoyuki Yoshikawa
Tomoko Goto
Kenichi Furuya
Yoshihiro Kikuchi
Publication date
01-04-2010
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 2/2010
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-010-0024-2

Other articles of this Issue 2/2010

International Journal of Clinical Oncology 2/2010 Go to the issue

Original Article

Health-related quality of life of colorectal cancer patients receiving oral UFT plus leucovorin compared with those with surgery alone

Case Report

Erythrocytosis caused by erythropoietin-producing thymic carcinoma

Review Article

Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: epidemiology, clinical findings, and prevention

Original Article

Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity

Original Article

The duration of functioning of a subcutaneous implantable port for the treatment of hematological tumors: a single institution-based study

Case Report

Aggressive recurrence of gastric cancer as a granulocyte-colony-stimulating factor-producing tumor
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits